Key result
Spironolactone 25 mg daily did not affect overall health care-related costs in ambulatory HFpEF patients, with average annual costs of €1,118 per patient primarily driven by hospitalization.
Why the study?
Heart failure with preserved ejection fraction is a leading cause for hospitalization, but its overall health care-related costs and the effect of spironolactone remained unclear.
Does spironolactone reduce health care-related costs in ambulatory patients with heart failure with preserved ejection fraction?
RCT (n=422)
double-blind
randomized
Yes
Does spironolactone reduce health care-related costs in ambulatory patients with heart failure with preserved ejection fraction?
In a relatively young and oligosymptomatic HFpEF cohort, annual healthcare costs were lower than expected and were not significantly affected by spironolactone therapy.
No takes yet. Share an insight, caveat, or question.
Spironolactone yields no cost savings in ambulatory HFpEF; extends neutral economic data for MRA therapy in preserved ejection fraction.
Hashemi et al. (2020) conducted an RCT in heart failure with preserved ejection fraction (HFpEF) (n=422). spironolactone vs. placebo was evaluated on health care-related costs. Spironolactone 25 mg daily did not affect overall health care-related costs in ambulatory HFpEF patients, with average annual costs of €1,118 per patient primarily driven by hospitalization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: